{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:40:32Z","timestamp":1776444032128,"version":"3.51.2"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,17]]},"abstract":"<jats:p>The World Health Organization, in its Guidance for Best Practices for Clinical Trials, recently emphasized the adoption of a core outcome set (COS) to promote standardization and transparency in trial reporting. A core outcome domain set (CODS) is a crucial first step before developing a COS, as it defines the key areas or domains that should be measured. Despite previous attempts, CODS\/COS for vitiligo clinical trials are still not widely used. To explore barriers and facilitators to implementing the vitiligo CODS, we conducted two complementary surveys. The first targeted corresponding authors of vitiligo randomized controlled trials and the second survey invited Editors-in-Chief of five leading dermatological journals.<\/jats:p>","DOI":"10.1093\/bjd\/ljag024","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:25:29Z","timestamp":1770290729000},"page":"948-951","source":"Crossref","is-referenced-by-count":0,"title":["Core outcome set in vitiligo: perspectives from the frontline of research and publishing. What do trialists and editors of five leading dermatology journals really think?"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5776-1466","authenticated-orcid":false,"given":"Viktoria","family":"Eleftheriadou","sequence":"first","affiliation":[{"name":"New Cross Hospital, The Royal Wolverhampton NHS Trust , Wolverhampton ,","place":["UK"]},{"name":"Walsall Manor Hospital, Walsall Healthcare NHS Trust , Walsall ,","place":["UK"]},{"name":"College of Medicine and Health, University of Birmingham , Birmingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahnawaz","family":"Towheed","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote School of Medicine, McMaster University , Hamilton, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanna C A C","family":"Prinsen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, VU University Medical Center , Amsterdam ,","place":["the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Nikoletopoulou","sequence":"additional","affiliation":[{"name":"New Cross Hospital, The Royal Wolverhampton NHS Trust , Wolverhampton ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry\u00a0W","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Henry Ford Health , Detroit, MI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), IMRB \u2013 Paris-Est Cr\u00e9teil University , INSERM U955, Cr\u00e9teil ,","place":["France"]},{"name":"Department of Dermatology, Henri-Mondor University Hospital , Assistance Publique \u2013 H\u00f4pitaux de Paris, Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"2026041711414327800_ljag024-B1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET handbook: version 1.0","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"key":"2026041711414327800_ljag024-B2","volume-title":"Guidance for Best Practices for Clinical Trials","author":"World Health Organization","year":"2024"},{"key":"2026041711414327800_ljag024-B3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/pcmr.12354","article-title":"Vitiligo Global Issues Consensus Group. Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus","volume":"28","author":"Eleftheriadou","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"2026041711414327800_ljag024-B4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/bjd\/ljac074","article-title":"Has the core outcome (domain) set for vitiligo been implemented? An updated systematic review on outcomes and outcome measures in \u00advitiligo randomized clinical trials","volume":"188","author":"Eleftheriadou","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026041711414327800_ljag024-B5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1186\/s13063-021-05891-5","article-title":"A survey of knowledge, perceptions and use of core outcome sets among clinical trialists","volume":"22","author":"Bellucci","year":"2021","journal-title":"Trials"},{"key":"2026041711414327800_ljag024-B6","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/ced\/llaf191","article-title":"How do atopic dermatitis trialists perceive the Harmonising Outcomes Measurement in Eczema (HOME) core outcome set? A survey study from the HOME initiative","volume":"50","author":"Gilad","year":"2025","journal-title":"Clin Exp Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag024\/66776297\/ljag024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/5\/948\/66776297\/ljag024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/5\/948\/66776297\/ljag024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:41:52Z","timestamp":1776440512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/5\/948\/8463101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":6,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,2,5]]},"published-print":{"date-parts":[[2026,4,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag024","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,2,5]]}}}